Monitoring plasma nucleosome concentrations to measure disease response and progression in dogs with hematopoietic malignancies
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0281796 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Heather Wilson-Robles und 10 weiteren Autor:innen. Beteiligte Einrichtung: Small Animal Clinical Sciences Department, Texas A&M University, College Station, Texas, United States of America. Hauptthemen laut MEDLINE: Neoplasms, Hematologic Neoplasms, Dog Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hematopoietic malignancies are extremely common in pet dogs and represent nearly 30% of the malignancies diagnosed in this population each year. Clinicians commonly use existing tools such as physical exam findings, radiographs, ultrasound and baseline blood work to monitor these patients for treatment response and remission. Circulating biomarkers, such as prostate specific antigen or carcinoembryonic antigen, can be useful tools for monitoring treatment response and remission status in human cancer patients. To date, there has a been a lack of useful circulating biomarkers available to veterinary oncology patients.
Methods
Circulating plasma nucleosome concentrations were evaluated at diagnosis, throughout treatment and during remission monitoring for 40 dogs with lymphoma, acute myelogenous leukemia and multiple myeloma. Additionally, C-reactive protein and thymidine kinase-1 levels were recorded.
Results
Plasma nucleosome concentrations were significantly higher at diagnosis and progressive disease than they were when dogs were in remission. All but two dogs had plasma nucleosome concentrations that returned to the low range during treatment. These two dogs had the shortest progression free and overall survival times. Dogs with the highest plasma nucleosome concentrations had a significantly shorter first progression free survival than dogs with lower plasma nucleosome concentrations at diagnosis. Plasma nucleosome concentrations correlated better with disease response and progression than either thymidine kinase or C reactive protein.
Conclusions
Plasma nucleosome concentrations can be a useful tool for treatment monitoring and disease progression in dogs with hematopoietic malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Small Animal Clinical Sciences Department, Texas A&M University, College Station, Texas, United States of America.
- Volition Veterinary Diagnostics Development, Henderson, Nevada, United States of America.
- Belgian Volition SRL, Parc Scientifique Crealys, Isnes, Belgium.
- Volition America LLC, Henderson, Nevada, United States of America.
ORCID-Profile: Heather Wilson-Robles
Zitieren
APA
Wilson-Robles, H., Warry, E., Miller, T., Jarvis, J., Matsushita, M., Miller, P., Herzog, M., Turatsinze, J. V., Kelly, T. K., Butera, S. T., & Michel, G. (2023). Monitoring plasma nucleosome concentrations to measure disease response and progression in dogs with hematopoietic malignancies. PLOS ONE. https://doi.org/10.1371/journal.pone.0281796
Vancouver
Wilson-Robles H, Warry E, Miller T, Jarvis J, Matsushita M, Miller P, et al. Monitoring plasma nucleosome concentrations to measure disease response and progression in dogs with hematopoietic malignancies. PLOS ONE. 2023. doi:10.1371/journal.pone.0281796
BibTeX
@article{WilsonRobles2023,
author = {Wilson-Robles, Heather and Warry, Emma and Miller, Tasha and Jarvis, Jill and Matsushita, Matthew and Miller, Pamela and Herzog, Marielle and Turatsinze, Jean-Valery and Kelly, Theresa K and Butera, S Thomas and Michel, Gaetan},
title = {Monitoring plasma nucleosome concentrations to measure disease response and progression in dogs with hematopoietic malignancies},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0281796}
}
EUVIMED